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ABSTRACT
Background: In cases using a budesonideformoterol combination inhaler, many patients are started on
fixed-dose treatment at 64018 μg (4 puffs) daily, but there are no guidelines yet regarding the step-down
method when control has been maintained.
Methods: Patients with moderate asthma treated with either budesonide 400 μg and salmeterol 100 μg (GINA
step3 group) or salmeterolfluticasone 250 at 2 puffs (GINA step4 group) were enrolled and started on therapy
of budesonideformoterol 4 puffs. Thereafter, step-down to 2 puffs was performed if either of the following crite-
ria was met at 8-week intervals: fractional exhaled nitric oxide (FeNO)28 ppb plus asthma control test (ACT)
score 22, or ACT score 24 at 3 consecutive visits regardless of FeNO level. Thereafter, changes in ACT
score, the number of acute exacerbations and reliever use, and FeNO level were monitored through 48th week.
Results: Fifty-one patients, 27 in step3 group and 24 in step4 group, underwent step-down. ACT scores and
the number of reliever use remained stable in both groups even after step-down. In contrast, FeNO levels in-
creased gradually in step4 group, whereas in the step3 group they increased immediately after step-down.
Step-down was considered to be safely performed because the numbers of reliever use and those of moderate
or more severe exacerbations during the 48-week period has not changed significantly compared to before
step-down.
Conclusions: If complete control of asthma, not only of clinical symptoms but also airway inflammation, is
achieved by 3-6 months of fixed-dose budesonideformoterol 4 puffsday, it should be possible to safely per-
form step-down to 2 puffsday.
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INTRODUCTION
GINA1 and most other asthma treatment guidelines
recommend the use of an inhaled corticosteroid
(ICS)long-acting β2-agonist (LABA) combination in-
haler as the first-line choice of a controller for chronic
asthmatic patients for whom control with ICS mono-
therapy is difficult. Thus, in Japan as in many other
countries, two ICSLABA combination inhaler prepa-
rations are widely used: fluticasonesalmeterol (SM)
combination inhaler (SFC) and budesonidefor-
moterol combination inhaler.2 The guidelines are
clear in regard to step-up methods for treating poorly
controlled asthma, recommending ICS dose-
escalation3 as well as combined therapy with an
added controller. There is abundant evidence in sup-
port of those step-up methods, whereas there is only
limited evidence in support of step-down methods
when asthma has been controlled for a long time.
Recommendations in this regard go no further than
stating that step-down should be considered when
stable control of at least 3 months’ duration has been
confirmed, etc..1,2,4
Similarly, there are still few reports regarding step-
down methods for treatment of moderate asthma pa-
tients being controlled with an ICSLABA combina-
tion inhaler, the most commonly used such treatment
worldwide. The potent bronchodilating activity of
LABA preparations shows efficacy even at the time of
exacerbation of airway inflammation. This may lead
to delay of add-on anti-inflammatory therapy, which is
actually of greater importance. For this reason, the
US FDA has issued an alert in regard to continuous
use of LABA.5 Accordingly, there is a critical need in
clinical practice for establishment of guidelines for
step-down methods for ICSLABA combination inhal-
ers. Although a few reports of step-down methods for
SFC have been published,6-10 there have been none in
regard to budesonideformoterol, which is mainly
used in single inhaler maintenance and reliever ther-
apy (SMART) in many countries, except the United
States and Japan. Moreover, the few reports pub-
lished to date have focused on respiratory function
and clinical symptoms as indicators, while none have
compared airway inflammation, which is of greatest
concern.
We postulated that step-down of the drug dosage
following achievement of complete control of asthma,
in terms of not only the clinical symptoms but also
airway inflammation, would subsequently lead to a
safer long-term clinical course. On that basis, we car-
ried out step-down to 2 puffsday in adult patients
with persistent moderate asthma that was being con-
trolled with fixed-dose budesonideformoterol 4
puffsday therapy, and then compared the clinical
course during the following 48 weeks with the status
prior to the dosage step-down. The primary endpoint
was the change in the asthma control test (ACT)
score. At the same time, with the objective of confirm-
ing the long-term safety of the step-down therapy, the
respiratory function tests and the fractional exhaled
nitric oxide (FeNO) level was also measured and ana-
lyzed as an index of airway inflammation.
METHODS
The subjects of the study were adult outpatients of
the National Center for Global Health and Medicine
(Tokyo) or at Kohnodai Hospital (Chiba, Japan), aged
20 years or older, with persistent moderate asthma.
The diagnosis of asthma was defined as the presence
of compatible clinical history and pulmonary function
tests demonstrating variable airflow obstruction by
means of bronchodilator responsiveness (an increase
in FEV1 > 12% after inhalation of albuterol), or by
demonstrating bronchial hyperreactivity using meth-
acholine challenge (provocative concentration caus-
ing a 20% decrease in FEV 1 < 8 mgdL). The asth-
matics treated for at least 6 months with BUD 400
μgday plus SM 100 μgday combined therapy or
SFC 250 Diskus 2 puffsday (equivalent to BUD 1000
μgday and SM 100 μgday) therapy (GINA treat-
ment steps 3-4), in whom the disease was “well-
controlled” or “totally controlled”, i.e., an ACT score
of 20-25 points, were eligible. Current smokers, those
who had a smoking history (smoking index > 400)
and patients with suspected COPD with either non
reversible airflow obstruction or obvious low attenu-
ation area on chest CT were excluded from the analy-
sis. Moreover patients who had a respiratory tract in-
fection within the last 4 weeks were also excluded.
Patients with allergic rhinitis were eligible if their
rhinitis symptoms had fully settled down. Combined
use of an ICS and a controller other than an ICS
LABA combination inhaler was permitted, but chang-
ing the dosage of any drugs other than budesonide
formoterol during the study period was not permit-
ted.
The study had an open-label, dose comparison de-
sign for before and after changing the dosage (i.e.,
step-down). Written, informed consent was obtained
from each patient, followed by a 4-week observation
period after which the treatment stage commenced.
Before starting the observation period, the patient’s
adherence to the prior treatment was confirmed, and
instruction regarding inhalation was repeated. Then,
the study drug, dry powder inhaler of budesonide
formoterol at 64018 μg (4 puffs)day, was adminis-
tered, and step-down to 3209 μg (2 puffs)day was
performed when either of the following response cri-
teria was satisfied at the time of outpatient visits to
the hospital at 8-wk intervals: (1) FeNO showed a
clear trend of improvement and decreased to 28
ppb, while the ACT score was22 points, or if these
conditions were not met, (2) regardless of the FeNO
level, the ACT score was 24 points at 3 consecutive
visits.
Step-Down Method of BUDFM Inhaler
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Table　1　Baseline characteristics of the study population
GINA step3 group GINA step4 group p value
Patient number 27 24 -
Male : Female 12 : 15 11 : 13 0.92
Age (years old) 50.2 ± 8.8 48.9 ± 11.3 0.41
Asthma duration (years) 13.1 ± 11.7 13.9 ± 14.8 0.44
FEV1.0 (L) 2.28 ± 0.62 2.31 ± 0.69 0.42
% FEV1.0 (%) 74.4 ± 11.9 78.4 ± 11.6 0.18
BMI 23.7 ± 2.8 22.9 ± 1.9 0.48
Ex-smoker  8  5 0.26**
Allergic rhinitis none 12  9
seasonal 11 10 0.89*
perennial  4  5
Add-on controller none 17 10
LTRA  6 11 0.07*
theophylline  4  6
ACT score 23.1 ± 1.4 22.2 ± 1.6 0.07
FeNO (ppb) 44.5 ± 28.7 48.8 ± 31.1 0.35
Data are presented as mean ± SD. P-values of Student t-test (measured value), Fisher exact test* and chi-square test** are shown.
Step-down was followed by a 48-week study period.
The ACT score, respiratory function tests, the num-
ber of reliever, short-acting β2-agonists (SABA) use
one week, and the FeNO level were measured every
8 weeks, and other assessment parameters were the
number of moderate or more severe acute exacerba-
tions (i.e., events requiring treatment with a systemic
steroid for at least 3 days) and the number of dropout
cases due to the need for re-escalation of dosages.
FeNO was measured using NIOX-MINO (Aerocrine
Ltd., Solna, Sweden).11 The step-down criterion for
FeNO was decided with reference to the ATS guide-
line12 and the normal range for Japanese (15-37 ppb)
shown in the Japanese handbook for FeNO measure-
ment.13 In addition, we referred to the methods pre-
sented in earlier reports14-17 that compared the guide-
line treatment and methods that decided the treat-
ment strategy by also measuring FeNO. In particular,
the above-described step-down criterion (2) for pa-
tients showing a continuously high FeNO level, the
ACT score 24 points at 3 consecutive visits seem-
ingly very conservative, was decided primarily on the
basis of the Japanese guideline,2 which aimed for
more strict asthma control than any other guidelines.
Performance of this clinical study was approved by
the Ethics Committee of the National Center for
Global Health and Medicine (2009-795). All measure-
ment values are presented as means ± SD. Differ-
ences between populations were analyzed for signifi-
cance using Student’s t-test, the chi-square test (with-
out continuity correction), and Fisher’s exact test, us-
ing a significance level of 0.1 (as used in comparison
of general background factors). Comparisons be-
tween baseline and post-treatment measured values
were analyzed using the paired Student’s t-test, the
Cochran-Cox test, and the log-rank test.
RESULTS
In total, 54 asthma patients were enrolled in the
study. Analyses were performed for 51 patients, after
exclusion of 3 patients for whom step-down could not
be performed because of failure to satisfy the step-
down criteria during the 48-week test period. The
male to female ratio was 23 : 28, and the mean age
was 49.8 ± 10.1 years (range: 23-81 years). The mean
duration of asthma was 13.4 ± 12.6 years, while the
mean FEV 1.0% was 76.2% ± 11.8%. The prior treat-
ment was a combination of BUD 400 μgday and SM
100 μgday, corresponding to GINA treatment step 3
(step3 group), in 27 patients, and SFC 250 Diskus 2
puffsday, corresponding to GINA treatment step 4
(step4 group), in 24 patients. Significant differences
in the background factors between the two patient
groups were found in regard to the concomitant con-
troller drugs and baseline ACT scores, but no other
factors were significant (Table 1).
The mean treatment time required until step-down
was possible was 13.2 ± 5.6 weeks in step3 group and
23.4 ± 10.1 weeks in step4 group, with the latter being
significantly longer (p < 0.01, Kaplan-Meier method,
log-rank test). Because of a persistently high FeNO
level, the possibility of step-down was based on meet-
ing criterion (2) rather than criterion (1) for 427 pa-
tients in the step3 group and 524 patients in step4
group.
At the time of step-down, the mean ACT score had
significantly improved from the baseline score as a
result of the fixed-dose budesonideformoterol 4
puffsday therapy: from 23 ± 1.28 to 24.31 ± 1.01 in
step3 group and from 22.15 ± 1.57 to 24.08 ± 1.32 in
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Fig.　1　The changes in mean Asthma Control Test (ACT) score before and after the step-
down. *p < 0.01 using t-test from the time step-down was initiated (week 0).
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Fig.　2　The changes in mean number of weekly SABA use before and after the step-
down. P-values of Student t-test (measured value) are shown. N.S., not signifi cant.
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step4 group (p < 0.01, t-test). In step3 group, the ACT
score during the 48-week period following step-down
remained nearly the same as prior to step-down. In
step4 group, which can be considered to have had
more serious asthma, the ACT score decreased
gradually following step-down, and it had decreased
significantly at the 24-week point (23.38 ± 1.33, p <
0.01). However, even after 48 weeks, it had not de-
creased to the score recorded before starting
budesonideformoterol (Fig. 1).
Similarly, the mean number of SABA use one week
at the time of step-down had significantly improved
from the baseline: from 2.89 ± 2.93 to 0.38 ± 0.52 in
step3 group and from 3.98 ± 2.55 to 0.68 ± 0.76 in step
4 group (p < 0.01, t-test). In both groups, the number
of weekly SABA use during the 48-week period fol-
lowing step-down remained almost same as prior to
step-down (Fig. 2). In contrast, the respiratory func-
tion tests such as FVC, FEV1.0 and MMF revealed no
remarkable change before and after step down (Table
2).
In terms of the FeNO level, step-down was per-
Step-Down Method of BUDFM Inhaler
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Fig.　3　The changes in mean fractional exhaled nitric oxide (FeNO) values before and after 
the step-down. *p < 0.01 using t-test from the time step-down was initiated (week 0).
*
*
*
*
*
*
60
50
40
30
20
10
0
-32 -24 -16 -8 0 8 16 24 32 40 48 weeks
step4 group
step3 group
(ppb)
BUD/FM 640/18 Pg 
320/9 Pg 
F
eN
O
 le
ve
l
Table　2　The changes of Spirometry parameters before and after the step-down
GINA step3 group (n = 27) GINA step4 group (n = 24)
Before entry 0 wk 48 wks after step-down Before entry 0 wk
48 wks after 
step-down
FVC 3.01 ± 0.88  3.18 ± 0.51 2.94 ± 1.11 2.81 ± 1.01 3.03 ± 1.33 2.77 ± 0.97
FEV1.0 2.28 ± 0.62  2.41 ± 0.55 2.25 ± 0.87 2.31 ± 0.69 2.35 ± 0.93 2.33 ± 0.72
% FEV1.0 74.4 ± 11.9 72.6 ± 9.7 76.4 ± 13.5 78.4 ± 11.6 76.5 ± 16.2 79.4 ± 12.4
MMF 1.82 ± 0.95  1.91 ± 1.35 1.95 ± 1.29 1.68 ± 0.98 1.61 ± 1.15 1.74 ± 1.31
V50 1.68 ± 1.21  1.84 ± 1.57 1.77 ± 1.23 1.59 ± 0.87 1.67 ± 0.74 1.60 ± 1.04
V25 0.79 ± 0.77  0.87 ± 0.96 0.84 ± 0.99 0.91 ± 0.96 1.11 ± 1.36 1.04 ± 0.91
Data are presented as mean ± SD. All the values revealed no signifi cant change before and after step-down using ANOVA.
formed in both patient groups following confirmation
of significant improvement due to the fixed-dose
budesonideformoterol 4 puffsday therapy (decreas-
ing from 44.5 ± 28.7 ppb to 25.3 ± 9 ppb in step3
group and from 48.8 ± 31.1 ppb to 26.5 ± 7.4 ppb in t
step4 group; p < 0.01). In step3 group, significant de-
terioration of the FeNO level was seen at 8 weeks fol-
lowing step-down (39.4 ± 25.5 ppb) (p < 0.01), but
from 40 weeks onward, the significant difference dis-
appeared, and there was a return to the trend of im-
provement. In step4 group, there was gradual deterio-
ration of the FeNO level following step-down, show-
ing significant worsening at 39.6 ± 23.6 ppb after 24
weeks. However, as seen for the ACT score, even af-
ter 48 weeks, the FeNO level never increased to the
level recorded before starting budesonideformoterol
(Fig. 3).
Two patients in step4 group dropped out of the
study (after 8 weeks) due to the need for re-
escalation of the budesonideformoterol dosages fol-
lowing step-down. Moderate or more severe exacer-
bations of asthma were experienced by 6 patients
(22%) in the step3 group, but only 3 in step4 group.
Thus, in step4 group patients, when the dropout
above is added, it can be presumed that adverse
events occurred in a total of 5 (21%) patients. Six pa-
tients in each patient group had experienced exacer-
bations during the 6 months of prior treatment.
Therefore, it appears that there was no significant
change in the frequency of exacerbations occurring
between before and after dosage step-down.
DISCUSSION
We proposed and investigated the clinical validity of
simple clinical criteria to enable safe step-down of the
drug dosage from fixed-dose budesonideformoterol
4 puffsday therapy for asthma. The results of obser-
vations performed over a 48-week period following
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step-down indicated that stable control of the asthma
had been maintained in terms of the ACT score, the
number of SABA use and those of exacerbations as
clinical indicators. Although the ACT score, which
has already been established as a standardized end-
point for clinical practice,18 showed a significant dif-
ference before and after step-down in step4 group,
taking a report that minimally important difference of
ACT score was 3 points,19 it might be deemed as no
clinical significance. Moreover the number of SABA
use, those of acute exacerbations and Spirometry pa-
rameters, which is more commonly used as a general
assessment parameter, revealed no deterioration af-
ter step-down.
However, the FeNO level, which is an indicator of
eosinophilic airway inflammation, did not necessarily
demonstrate any changes that correlated with the
aforementioned clinical indicators, such as an imme-
diate re-increase after step-down. In addition, because
the transiently elevated FeNO level also showed a
subsequent trend of gradual improvement, the pre-
sent findings suggest the possibility that use of the
FeNO level as the sole marker for treatment may lead
to the over-administration of controller therapy such
as ICS.
The present findings do not contradict the results
of earlier reports14,15 and a meta-analysis20 that found
that, even if the therapeutic approach is decided on
the basis of the addition of FeNO measurement to the
guideline therapy formulated on the use of clinical
symptoms and respiratory function as indicators,
there may be no significant improvement in asthma
control, and there may also be an increase in the use
of an ICS compared with conventional therapy. It can
be surmised that these results are in agreement with
the current positioning of FeNO, which has not been
evaluated to the same extent as sputum eosinophils
as a biomarker of eosinophilic airway inflammation.
However, at the 48-week point following step-down,
FeNO also had not increased to the level seen prior
to the budesonideformoterol 4 puffsday inhalation
therapy, and it can be thought that control of airway
inflammation had been maintained to some extent.
Moreover, the mean treatment time until step-down
was feasible on the basis of our proposed criteria was
13.2 weeks for step3 group, and 23.4 weeks for step 4
group, which might have been due to the effects of
continuation of the 4-puff therapy for a longer period
of time in this group. These time intervals are in
agreement with most asthma guidelines’ recommen-
dation that step-down be considered after confirming
disease stability for 3-6 months.
On the basis of the findings described above, we
believe that our initial hypothesis, that step-down of
the drug dosage after attaining a nearly normal state
in terms of not only the clinical symptoms but also
airway inflammation would lead to a safer subsequent
long-term clinical course, is clinically significant.
As noted earlier, there are still few reports regard-
ing step-down in treatment of asthma patients being
controlled with an ICSLABA combination inhaler. It
has been reported that patients whose asthma had
been controlled by 12-week therapy with SFC 250
showed no deterioration in terms of the frequency of
acute exacerbations for 3 months even following a
subsequent step-down to SFC 100 with results signifi-
cantly superior to those in patients in an ICS mono-
therapy (FP 500 μgday) group.6 There have been a
few similar reports regarding SFC.7-10 However, in
each study, it was shown that step-down from SFC
250 to SFC 100 tended to result in a slight deteriora-
tion of the endpoints, including the peak flow,
symptom-free days, etc.. Nevertheless, each of those
studies had a short observation period of only 3-6
months, and there have been no reports describing
either the safety over a long period of approximately
1 year or the anti-inflammatory effects. In addition, re-
ports regarding step-down of budesonideformoterol
therapy are limited to treatment based on AMD (ad-
justable maintenance dosing)21 or SMART.22 Each of
these studies dealt with treatment that adjusted the
inhaled drug dose according to the clinical symp-
toms, and there have been no reports regarding step-
down of fixed-dose therapy.
There still remain unresolved issues in our under-
standing of FeNO. One of the major issues is that
there are at least some asthma patients in whom a
high FeNO level persists despite control of their
asthma. In the present study, step-down was per-
formed in a total of 9 patients in accordance with our
postulated criterion (2) while a high FeNO level per-
sisted, but each of those patients had allergic rhinitis.
However, there were no asthma exacerbations follow-
ing step-down in these patients. It is known that there
is a high incidence of allergic rhinitis in patients with
persistently high FeNO levels despite asthma control
having been achieved,12 and that extra caution is
needed when performing step-down in patients with
allergic rhinitis.
Our division of patients into two groups, namely a
BUD400SM100 (step3) group and an SFC250 (step
4) group, based on the prior treatment, was strongly
influenced by the circumstances unique to Japan.
There are currently only two ICSLABA combination
inhalers available for clinical use in Japan, and
budesonideformoterol was only introduced in the
year the study was conducted. Therefore, most of our
patients were switched to budesonideformoterol
from those 2 treatments. Even in our clinical study
concerning the anti-inflammatory effects of fixed-dose
budesonideformoterol 4 puffsday therapy,23 these 2
prior treatments accounted for more than 90% of the
patients, and a difference in the prognosis following
step-down was seen between the 2 treatment groups.
For that reason, we decided to divide the patients into
2 groups at the start of the present study. The step4
Step-Down Method of BUDFM Inhaler
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group showed a low ACT score despite not only the
ICS dosage being high, but also the use of a greater
number of concomitant controller drugs, indicating
that the group included a greater number of more se-
vere cases of asthma. Although there was a differ-
ence in the clinical course following step-down, good
asthma control was achieved for approximately 1 year
in both patient groups after step-down. Therefore this
fact suggested that if complete control of asthma, not
only of clinical symptoms but also airway inflamma-
tion, is achieved by 3-6 months of fixed-dose
budesonideformoterol 4 puffsday, it should be pos-
sible to safely carry out step-down to 2 puffsday for
most patients with asthma of moderate severity.
The results of this study should be considered
along with the limitations. First, the study was small,
with only about 25 patients per group. The primary
endpoint ACT score showed a significant difference
before and after step-down in step4 group, but the
number of SABA use and those of acute exacerba-
tions, which is more commonly used as a general as-
sessment parameter, did not. One possible reason for
that could be that the 21-22% exacerbation rate was
lower than the rate of approximately 27% reported for
2 other studies14,15 that similarly used FeNO as an in-
dicator, but we think that it can actually be attributed
to the small number of patients. Second, this study
had an open-label, non-placebo, non-crossover de-
sign, comparing the data recorded before and after
changing the dosage. Therefore, the presence of bias
in the assessment of the assayed parameters cannot
be ruled out. The difficulty of using FeNO as an as-
sessment parameter has already been described.
Nevertheless, considering the paucity of reports re-
garding the step-down method, the present study can
be thought to have great significance because it has
generated new evidence. In terms of budesonidefor-
moterol in particular, the possibility has also been
highlighted of exacerbation of not only clinical symp-
toms22 but also airway inflammation,24 even if
SMART is added to continuous therapy at 2 puffs
day. Hence, we believe that the present study, in
which changes in FeNO were monitored over the
long-term, will serve as a reference point for carrying
out similar, larger-scale, clinical trials in the future.
As a conclusion, simple clinical criteria were pro-
posed for deciding to step-down from fixed-dose
budesonideformoterol 4 puffsday therapy to 2
puffsday for asthma patients. It was suggested that it
should be possible to safely perform step-down to 2
puffsday following the achievement of complete con-
trol of asthma for a period of 3-6 months, regardless
of prior treatment. Additional studies are needed to
expand on the current findings in a larger sample,
and determine whether the effects in airway inflam-
mation can be maintained for the long term and re-
duce exacerbations even after step down is per-
formed.
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